This study investigates a method to predict medical outcome of cholinesterase inhibitors in patients with Alzheimer’s disease (AD) and vascular dementia (VaD). Van Gool predicts that patients with cholinergic deficit symptoms will benefit from treatment whereas patients without will experience side effects because of overstimulation of the cholinergic system. We predicted that AD and VaD patients with a longer RT experience fewer side effects than patients with a faster response and that VaD patients have a longer RT than AD patients. A number of 71 patients with AD or VaD diagnosis were included. A sustained attention task was administered, as well as the MMSE and a questionnaire about side effects. Results indicated that VaD patients with...
The treatment of Alzheimer’s disease (AD) was revolution-ized by the development of cholinesterase i...
The involvement of an impaired cholinergic neurotransmission in the pathophysiology of cognitive imp...
Background: Approximately 850,000 people live with dementia in the UK. Vascular dementia (VaD) accou...
This study investigates a method to predict medical outcome of cholinesterase inhibitors in patients...
Background: Vascular dementia is a cognitive decline with functional deterioration caused by cerebro...
grantor: University of TorontoCholinesterase inhibitors (ChEIs) are the only pharmacothera...
Cholinergic hypofunction is a trait of Alzheimer’s disease (AD)and of other forms of dementias such ...
OBJECTIVE: To investigate whether cholinesterase inhibitors (ChEIs) are associated with slower cogni...
Contains fulltext : 50920.pdf (preprint version ) (Open Access)The treatment of Al...
Cholinesterase inhibitors (ChEIs) are the primary pharmacologic treatment for dementia. Their effica...
The improvement in cognitive performances due to cholinesterase inhibitors (ChEls) is not homogeneou...
BACKGROUND: Evidence from open label studies has indicated that patients with dementia with Lewy bod...
Although the exact pathogenesis of Alzheimer’s disease (AD) remains unclear, the widespread loss of ...
The most widely studied and used therapies for Alzheimer\u27s disease (AD) are based on improving ch...
BackgroundThe mainstay of therapy for many neurodegenerative dementias still relies on acetylcholine...
The treatment of Alzheimer’s disease (AD) was revolution-ized by the development of cholinesterase i...
The involvement of an impaired cholinergic neurotransmission in the pathophysiology of cognitive imp...
Background: Approximately 850,000 people live with dementia in the UK. Vascular dementia (VaD) accou...
This study investigates a method to predict medical outcome of cholinesterase inhibitors in patients...
Background: Vascular dementia is a cognitive decline with functional deterioration caused by cerebro...
grantor: University of TorontoCholinesterase inhibitors (ChEIs) are the only pharmacothera...
Cholinergic hypofunction is a trait of Alzheimer’s disease (AD)and of other forms of dementias such ...
OBJECTIVE: To investigate whether cholinesterase inhibitors (ChEIs) are associated with slower cogni...
Contains fulltext : 50920.pdf (preprint version ) (Open Access)The treatment of Al...
Cholinesterase inhibitors (ChEIs) are the primary pharmacologic treatment for dementia. Their effica...
The improvement in cognitive performances due to cholinesterase inhibitors (ChEls) is not homogeneou...
BACKGROUND: Evidence from open label studies has indicated that patients with dementia with Lewy bod...
Although the exact pathogenesis of Alzheimer’s disease (AD) remains unclear, the widespread loss of ...
The most widely studied and used therapies for Alzheimer\u27s disease (AD) are based on improving ch...
BackgroundThe mainstay of therapy for many neurodegenerative dementias still relies on acetylcholine...
The treatment of Alzheimer’s disease (AD) was revolution-ized by the development of cholinesterase i...
The involvement of an impaired cholinergic neurotransmission in the pathophysiology of cognitive imp...
Background: Approximately 850,000 people live with dementia in the UK. Vascular dementia (VaD) accou...